Anzeige
Mehr »
Lynx Broker
Login
Montag, 19.08.2019 Börsentäglich über 12.000 News von 605 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrFDA approves first spinal tether implant for correcting childhood scoliosis
FrAgilent unveils combination real-time cell imager and analyzer following ACEA acquisition
FrMonopar files for $40M IPO to test chemo side effect drug
FrChutes & Ladders-GlaxoSmithKline poaches Merck KGaA exec to run U.S. pharma
FrAlector, Prevail trade blows over alleged misuse of confidential information
DoHow nematode worms could inspire safer opioid use
DoEuroBiotech Report-Autolus delay, Novartis sale, Sonnet deal, Y-mAbs and the U.K.
DoEuroBiotech: More Articles of Note
DoMacroGenics, Incyte's PD-1 med to face off with Merck's Keytruda in a first for cancer R&D
DoIn conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capital
DoV-Wave nabs FDA breakthrough designation for its heart pressure shunt implant
DoUltragenyx snags option on antisense startup GeneTx
DoY-mAbs ramps up head count in post-IPO hiring spree
DoAstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival
MiTreating glioblastoma with a Ziopharm drug and IL-12 gene therapy
MiZipLine's wound closure alternative outperforms staples, sutures in two studies
MiRegeneron's Praluent sidekick moves the needle on 'bad' cholesterol
MiFDA cancer office taps Syapse for real-world evidence development
MiZeldin joins Immunovant as CMO months after Acceleron split
MiD&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
MiRenovacor bags $11M to push precision medicine for rare heart disease
DiXontogeny's Landos Biopharma reels in $60M to ramp up IBD program
DiDatavant, PCORnet to build real-world data network spanning 60M patients
DiDeciphera soars as phase 3 cancer data tee up FDA filing
DiNovartis sells phase 3 rare disease drug to Pharming